Clazosentan: First Approval

被引：0
作者：
Arnold Lee
机构：
[1] Springer Nature,
来源：
Drugs | 2022年 / 82卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Clazosentan (PIVLAZ™) is a small molecule, endothelin (ET) A receptor-selective antagonist being developed by Idorsia Pharmaceuticals. ETA receptor inhibition by clazosentan decreases ET-related cerebral vasospasm, which may occur after an aneurysmal subarachnoid haemorrhage. Clazosentan has been approved in Japan for use in the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischaemic symptoms after aneurysmal subarachnoid haemorrhage, following the results from the JapicCTI163369 and JapicCTI163368 phase III trials. This article summarises the milestones in the development of clazosentan leading to this first approval in this indication.
引用
收藏
页码：697 / 702
页数：5
相关论文
共 33 条
  • [1] Roux S(1997)Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm J Pharmacol Exp Ther 283 1110-1118
  • [2] Breu V(2005)Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction J Neurosurg 102 1101-1107
  • [3] Giller T(2005)Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation J Neurosurg 102 1108-1114
  • [4] Vatter H(2011)Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats Brain Res 1392 132-139
  • [5] Zimmermann M(2020)Association between vomiting and QT hysteresis: data from a TQT study with the endothelin A receptor antagonist clazosentan AAPS J 22 103-67
  • [6] Tesanovic V(2017)Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients Cerebrovasc Dis 44 59-1469
  • [7] Vatter H(2012)Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling Stroke 43 1463-31
  • [8] Zimmermann M(2013)Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2) Acta Neurochir Suppl 115 27-3021
  • [9] Tesanovic V(2008)Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial Stroke 39 3015-e648
  • [10] Chen G(2019)Reversal of vasospasm with clazosentan after aneurysmal subarachnoid hemorrhage: a pilot study World Neurosurg. 128 e639-17
1234